Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell ...

Read about how Crispr's robust pipeline for cardiovascular diseases holds blockbuster potential, with top-line results ...

Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.

Investors looking for stocks that can make dramatic gains can find some in the biopharmaceutical industry. Right now, there ...

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...

Due to manufacturing complexities, insurance delays, and the extensive preparation involved for patients, few individuals in the US have been dosed with Casgevy since it became commercially available.

The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...

Gene therapies are revolutionizing treatment for hemophilia A and sickle cell disease; however, they are saddled with hefty ...

They Are: CRSP, IMCR, GLUE, RIGL, CSTL. Since November 2023, CRISPR Therapeutics has been earning approvals for Casgevy, a gene-editing medicine, in various countries and regions. This new ...